Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective.

Ainslie GR, Davis M, Ewart L, Lieberman LA, Rowlands DJ, Thorley AJ, Yoder G, Ryan AM.

Lab Chip. 2019 Sep 27;19(19):3152-3161. doi: 10.1039/c9lc00492k.

PMID:
31469131
2.

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.

Lieberman LA, Zeng W, Singh C, Wang W, Otipoby KL, Loh C, Plavina T, Gorelik L, Ransohoff RM, Cahir-McFarland E.

Neurology. 2016 Jan 26;86(4):375-81. doi: 10.1212/WNL.0000000000002314. Epub 2015 Dec 30. Erratum in: Neurology. 2016 Aug 30;87(9):960.

3.

Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease.

Lieberman LA, Mizui M, Nalbandian A, Bossé R, Crispín JC, Tsokos GC.

Clin Immunol. 2015 Oct;160(2):286-91. doi: 10.1016/j.clim.2015.05.006. Epub 2015 May 16.

PMID:
25988858
4.

Lupus-prone mice fail to raise antigen-specific T cell responses to intracellular infection.

Lieberman LA, Tsokos GC.

PLoS One. 2014 Oct 31;9(10):e111382. doi: 10.1371/journal.pone.0111382. eCollection 2014.

5.

IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells.

Mizui M, Koga T, Lieberman LA, Beltran J, Yoshida N, Johnson MC, Tisch R, Tsokos GC.

J Immunol. 2014 Sep 1;193(5):2168-77. doi: 10.4049/jimmunol.1400977. Epub 2014 Jul 25.

6.

KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3⁺ regulatory T cells in MRL/lpr mice.

Koga T, Mizui M, Yoshida N, Otomo K, Lieberman LA, Crispín JC, Tsokos GC.

Autoimmunity. 2014 Nov;47(7):445-50. doi: 10.3109/08916934.2014.915954. Epub 2014 May 15.

7.

CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance.

Koga T, Hedrich CM, Mizui M, Yoshida N, Otomo K, Lieberman LA, Rauen T, Crispín JC, Tsokos GC.

J Clin Invest. 2014 May;124(5):2234-45. doi: 10.1172/JCI73411. Epub 2014 Mar 25.

8.

Complement depletion protects lupus-prone mice from ischemia-reperfusion-initiated organ injury.

Ioannou A, Lieberman LA, Dalle Lucca JJ, Tsokos GC.

Am J Physiol Gastrointest Liver Physiol. 2013 Feb 1;304(3):G283-92. doi: 10.1152/ajpgi.00371.2012. Epub 2012 Oct 25.

9.

The role of platelet factor 4 in local and remote tissue damage in a mouse model of mesenteric ischemia/reperfusion injury.

Lapchak PH, Ioannou A, Rani P, Lieberman LA, Yoshiya K, Kannan L, Dalle Lucca JJ, Kowalska MA, Tsokos GC.

PLoS One. 2012;7(7):e39934. doi: 10.1371/journal.pone.0039934. Epub 2012 Jul 6.

10.

The dysregulation of cytokine networks in systemic lupus erythematosus.

Apostolidis SA, Lieberman LA, Kis-Toth K, Crispín JC, Tsokos GC.

J Interferon Cytokine Res. 2011 Oct;31(10):769-79. doi: 10.1089/jir.2011.0029. Epub 2011 Aug 30. Review.

11.

The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity.

Lieberman LA, Tsokos GC.

J Biomed Biotechnol. 2010;2010:740619. doi: 10.1155/2010/740619. Epub 2010 Jun 6.

12.

Pathogenesis of human systemic lupus erythematosus: recent advances.

Crispín JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, Tsokos GC.

Trends Mol Med. 2010 Feb;16(2):47-57. doi: 10.1016/j.molmed.2009.12.005. Epub 2010 Feb 4. Review.

13.

Inhibition of Listeria monocytogenes infection by neurological drugs.

Lieberman LA, Higgins DE.

Int J Antimicrob Agents. 2010 Mar;35(3):292-6. doi: 10.1016/j.ijantimicag.2009.10.011. Epub 2009 Dec 23.

14.

A small-molecule screen identifies the antipsychotic drug pimozide as an inhibitor of Listeria monocytogenes infection.

Lieberman LA, Higgins DE.

Antimicrob Agents Chemother. 2009 Feb;53(2):756-64. doi: 10.1128/AAC.00607-08. Epub 2008 Nov 17.

15.

Interleukin-15-deficient mice develop protective immunity to Toxoplasma gondii.

Lieberman LA, Villegas EN, Hunter CA.

Infect Immun. 2004 Nov;72(11):6729-32.

16.

IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12.

Lieberman LA, Cardillo F, Owyang AM, Rennick DM, Cua DJ, Kastelein RA, Hunter CA.

J Immunol. 2004 Aug 1;173(3):1887-93.

18.

Costimulation in resistance to infection and development of immune pathology: lessons from toxoplasma.

Hunter CA, Lieberman LA, Mason N, Pepper M, Sague SL, Tato C, Zediak V.

Immunol Res. 2003;27(2-3):331-40. Review.

PMID:
12857979
19.

Regulatory pathways involved in the infection-induced production of IFN-gamma by NK cells.

Lieberman LA, Hunter CA.

Microbes Infect. 2002 Dec;4(15):1531-8. Review.

PMID:
12505525
20.

The role of cytokines and their signaling pathways in the regulation of immunity to Toxoplasma gondii.

Lieberman LA, Hunter CA.

Int Rev Immunol. 2002 Jul-Oct;21(4-5):373-403. Review.

PMID:
12486820
21.
22.

A role for inducible costimulator protein in the CD28- independent mechanism of resistance to Toxoplasma gondii.

Villegas EN, Lieberman LA, Mason N, Blass SL, Zediak VP, Peach R, Horan T, Yoshinaga S, Hunter CA.

J Immunol. 2002 Jul 15;169(2):937-43.

23.

Integrating mental health and home care services for AIDS patients.

Pessin N, Lindy D, Stricoff DJ, Lieberman LA, Parkin R, Goralewicz R, Holahan L, McHarry L, Hyer K.

Caring. 1993 May;12(5):30-4.

PMID:
10125245

Supplemental Content

Loading ...
Support Center